leisure time -WSS

leisure time

author：focus 2025-09-30 14:10:01 - browse：5922

the Federal Trade Commission building and its brown sign — Adobe

A federal judge ordered Wednesday that Novant Health can move forward with its plan to buy two North Carolina hospitals, denying the Federal Trade Commission’s request for an injunction.

The FTC sued to block the deal in January, arguing that it would give Novant control of more than 65% of the region’s inpatient market. The case, one seeking to block nearby hospitals from merging and creating an even more powerful dominant player, is the FTC’s bread and butter. The agency has shied away from challenging cross-market and vertical mergers, but this one is right in its wheelhouse, which makes the setback surprising.

Under the deal, announced early last year, Novant would buy two hospitals in the same county from for-profit Community Health Systems for $320 million. The hospitals, Lake Norman Regional Medical Center and Davis Regional Medical Center, are only a 25-minute drive from one another. Davis Regional used to be a full-service hospital, but is now a psychiatric hospital. The deal also includes a group of 24 doctors, a majority interest in an endoscopy center, and a holding in a planned surgery center.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： ASCO: AstraZeneca says CAR

WSS

Change Healthcare can notify patients about the breach, HHS says

How neuroscience research could help beat back brain cancer

At ASCO, AstraZeneca reports strong data for breast cancer drug

Gene therapy’s promise and the high cost of hope

Letters to First Opinion on caregivers, digital health, and more

Medicare must police algorithms in Medicare Advantage, Dems say

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Medicare details structure of new drug price negotiation program

Inari Medical to buy amputation prevention company LimFlow

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

DeepMind touts AlphaFold's new skills as protein folding AI models face off

In Memoriam: Notable people who died in 2023

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

In Memoriam: Notable people who died in 2023

At ASCO, AstraZeneca reports strong data for breast cancer drug

Wikipedia

ASCO: AstraZeneca says CAR

At ASCO, AstraZeneca reports strong data for breast cancer drug

Explaining an after

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

After Sarepta trial failure, Duchenne families brace for more debate

BMI, flaws aside, is found to be useful estimate of body fat in youth

knowledge

hotspot

knowledge

leisure time